GT
SAGE

Glenmede Trust’s Sage Therapeutics SAGE Stock Holding History

Glenmede Trust’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-335
Closed -$20K – 2048
2020
Q3 		$20K Sell
335
-119
-26% -$6.03K ﹤0.01% 1628
2020
Q2 		$18K Buy
454
+449
+8,980% +$16.3K ﹤0.01% 1636
2020
Q1 		$0 Hold
5
– – ﹤0.01% 3055
2019
Q4 		$0 Hold
5
– – ﹤0.01% 3114
2019
Q3 		$0 Buy
+5
New +$836 ﹤0.01% 3102

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Glenmede Trust's SAGE Position: Q4 2020 in Review

Glenmede Trust sold out of Sage Therapeutics (SAGE) in Q4 2020, closing a stake of 335 shares — an estimated $20K sold.

Glenmede Trust first reported a position in SAGE in Q3 2019 and held it in 5 quarters. The position peaked at $20K in Q3 2020. 249 funds tracked by Wall St. Rank hold SAGE as of Q4 2020.

  • Glenmede Trust reported no remaining Sage Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 335 Sage Therapeutics shares in Q4 2020, an estimated $20K.
  • Glenmede Trust first reported a position in Sage Therapeutics in Q3 2019 and held it in 5 quarters.
  • Glenmede Trust's Sage Therapeutics position peaked at $20K in Q3 2020.
  • 249 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.